The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Psoriasis bodypainting campaign puts dermatologists ‘in their patients’ shoes’
Top 10 Novartis Facts and Figures
Novartis employees give their time to the community
PrXolair® added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)
Combination treatment PrTafinlar® (dabrafenib) plus PrMekinist® (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy1
21 years of community service: Novartis takes part in annual Community Partnership Day in Canada
Novartis heart failure treatment PrEntresto™ (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan
Montrealer Janice Murray named President of Novartis in Canada
Each year for the past 12 years, Novartis employees have been giving back to the breast cancer community.
Kenyan community health education meetings & health camps supported through Novartis Canada International Volunteer Program
This site is intended for an audience in Canada.